Literature DB >> 2351925

The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.

A G Olsson1, G Ruhn, U Erikson.   

Abstract

The development of femoral atheroma after 1 year of treatment with diet and nicotinic acid plus fenofibrate was studied in 45 asymptomatic, hyperlipidaemic, middle-aged male subjects in a non-randomized controlled study. The median serum very low density lipoprotein (VLDL) cholesterol concentration and the low density lipoprotein (LDL) cholesterol concentration were lowered by 67% and 36%, respectively, in the treatment group. The median serum high density lipoprotein (HDL) cholesterol concentration was increased by 23%. Femoral atheroma was estimated by overall atherosclerosis score (OAS). Changes in femoral atherosclerosis were estimated by intrapair comparison of angiograms. Progression was found in 24% and 40% in the treatment and control groups, respectively. Regression occurred in 29% and 0%, respectively. The OAS decrease correlated with reductions in VLDL cholesterol and systolic blood pressure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351925     DOI: 10.1111/j.1365-2796.1990.tb00176.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  7 in total

Review 1.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

2.  A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.

Authors:  M J O'Kane; T R Trinick; M B Tynan; E R Trimble; D P Nicholls
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 3.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

4.  Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia.

Authors:  B Föger; H Drexel; T Hopferwieser; G Miesenböck; A Ritsch; M Lechleitner; G Tröbinger; J R Patsch
Journal:  Clin Investig       Date:  1994-03

Review 5.  Cholesterol and coronary disease--outstanding questions.

Authors:  M F Oliver
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

6.  Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality.

Authors:  P Rubba; P Pauciullo; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

Review 7.  Niacin dosing: relationship to benefits and adverse effects.

Authors:  D M Capuzzi; J M Morgan; O A Brusco; C M Intenzo
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.